Pharyngitis Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The pharyngitis treatment market size has grown steadily in recent years. It will grow from $2.27 billion in 2024 to $2.37 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to high prevalence and growing incidence of flu, rising prevalence of pharyngitis, growing awareness of pharyngitis, increasing access to healthcare, rising disposable incomes.

The pharyngitis treatment market size is expected to see strong growth in the next few years. It will grow to $2.99 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to adoption of rapid point-of-care tests, demand for personalized medicine, prevalence of antibiotic resistance, rising importance of hand hygiene. Major trends in the forecast period include advancements in research and development of pharyngitis therapies, digital health technologies, telehealth integration,.

The increasing transmission of strep throat is poised to drive the expansion of the pharyngitis treatment market. Strep throat is a contagious bacterial infection primarily affecting the throat and tonsils. Swift and effective treatment of strep throat with antibiotics is crucial for symptom relief, complication prevention, and reducing the risk of spreading the infection to others. For example, as of June 2022, data from the Centers for Disease Control and Prevention, a US-based government agency, reveals an annual occurrence of approximately 14,000 to 25,000 cases of invasive group A strep disease in the United States. Furthermore, strep-related diseases prompt 5.2 million outpatient visits and result in 2.8 million antibiotic prescriptions each year. Thus, the increased transmission of strep throat is a significant driver of growth in the pharyngitis treatment market.

The increasing incidence of influenza is expected to drive the growth of the pharyngitis treatment market. Influenza, commonly referred to as the flu, is a contagious respiratory illness caused by influenza viruses. Pharyngitis treatment is commonly used to manage the symptoms of influenza, including inflammation and irritation of the throat. These treatments are aimed at alleviating discomfort, relieving allergies, and preventing complications such as pneumonia and bronchitis. For example, in July 2023, the European Centre for Disease Prevention and Control (ECDC), a Sweden-based government agency, reported that during the 2022/2023 influenza season in the EU/EEA, the percentage of positive influenza specimens reached 42% in week 51 of 2022, with positivity remaining around 28% from week 5 to week 12 of 2023. As a result, the rising incidence of influenza is driving the growth of the pharyngitis treatment market.

Major companies operating in the pharyngitis treatment market are focusing on developing innovative solutions like oral monotherapy to improve patient compliance and offer effective, convenient treatment options. Oral monotherapy refers to using a single medication administered orally to treat a specific condition, rather than combining multiple treatments. This approach simplifies the treatment regimen while delivering the desired therapeutic effect. For example, in December 2023, Novartis AG, a Switzerland-based pharmaceutical company, received FDA approval for Fabhalta (iptacopan), marking it as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH). This approval provides a significant advancement by offering a new treatment that enhances hemoglobin levels, removing the need for blood transfusions.

In November 2022, TPG Inc., a US-based private equity firm, acquired a majority stake in iNova Pharmaceuticals for $1.3 billion (USD 2 billion). This acquisition aims to accelerate growth, expand market reach, and enhance product offerings in the healthcare sector, particularly in Southeast and North Asia. iNova Pharmaceuticals, based in Singapore, provides over-the-counter products designed to relieve symptoms of pharyngitis, including throat lozenges and pain relievers.

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Genentech Inc., Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Pliva Hrvatska D.o.o., LivaNova PLC, Genentech Inc.

North America was the largest region in the pharyngitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharyngitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharyngitis treatment market consists of sales of antibiotics, antiviral drugs and antifungal medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Pharyngitis treatment involves the care and management of individuals who are dealing with inflammation in the oropharynx, commonly referred to as the throat. Pharyngitis can have multiple causes, including bacterial or viral infections, allergies, trauma, malignancy, reflux, and exposure to certain toxins.

The primary classes of drugs used in pharyngitis treatment encompass beta-lactams, macrolides, cephalosporins, fluoroquinolones, tetracyclines, and other categories. Beta-lactams are a class of antibiotics distinguished by the presence of a beta-lactam ring in their chemical structure. Infections can stem from various sources, including viral and bacterial agents. Additionally, treatments are administered through various modes, such as oral, intravenous, intramuscular, and others, catering to diverse end-users, including hospitals, homecare settings, specialty centers, and more.

The pharyngitis treatment market research report is one of a series of new reports that provides pharyngitis treatment market statistics, including pharyngitis treatment industry global market size, regional shares, competitors with a pharyngitis treatment market share, detailed pharyngitis treatment market segments, market trends and opportunities and any further data you may need to thrive in the pharyngitis treatment industry. This pharyngitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.